NLRP3 and cancer: In summary, across cancer and fibrotic diseases, inflammasome inhibition can curb EMT by disrupting NLRP3-dependent IL1β signalling and its engagement of MAPK, NF-κB, and TGF-β/Smad pathways in order to achieve particular treatment goals.